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Clinical impact of the subclonal architecture and mutational
complexity in chronic lymphocytic leukemia
F Nadeu1,2, G Clot1,2, J Delgado1,2,3, D Martín-García1,2, T Baumann3, I Salaverria1,2, S Beà1,2, M Pinyol2,4, P Jares1,2,3, A Navarro1,2,
H Suárez-Cisneros4, M Aymerich1,2,3, M Rozman1,2,3, N Villamor1,2,3, D Colomer1,2,3, M González2,5, M Alcoceba2,5, MJ Terol6, B Navarro6,
E Colado7, ÁR Payer7, XS Puente2,8, C López-Otín2,8, A López-Guillermo1,2,3,9, A Enjuanes2,4 and E Campo1,2,3,9
Genome studies of chronic lymphocytic leukemia (CLL) have revealed the remarkable subclonal heterogeneity of the tumors, but the
clinical implications of this phenomenon are not well known. We assessed the mutational status of 28 CLL driver genes by deep-
targeted next-generation sequencing and copy number alterations (CNA) in 406 previously untreated patients and 48 sequential
samples. We detected small subclonal mutations (0.6–25% of cells) in nearly all genes (26/28), and they were the sole alteration in 22%
of the mutated cases. CNA tended to be acquired early in the evolution of the disease and remained stable, whereas the mutational
heterogeneity increased in a subset of tumors. The prognostic impact of different genes was related to the size of the mutated clone.
Combining mutations and CNA, we observed that the accumulation of driver alterations (mutational complexity) gradually shortened
the time to ﬁrst treatment independently of the clonal architecture, IGHV status and Binet stage. Conversely, the overall survival was
associated with the increasing subclonal diversity of the tumors but it was related to the age of patients, IGHV and TP53 status of the
tumors. In conclusion, our study reveals that both the mutational complexity and subclonal diversity inﬂuence the evolution of CLL.
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INTRODUCTION
Genome-wide studies have recently elucidated the mutational
landscape of chronic lymphocytic leukemia (CLL) characterized by
few genes mutated at moderate frequency and a larger amount
altered in less than 5% of the cases.1–6 The remarkable genomic
plasticity of this disease has been further emphasized by the
subclonal composition,4,6 the identiﬁcation of convergent muta-
tional evolution in few patients7,8 and the different patterns of
clonal diversiﬁcation upon disease progression.9–12 This inter- and
intra-tumor mutational diversity may be a relevant cause of the
heterogeneous clinical outcome of these patients.
Different individual mutated genes have demonstrated their
prognostic value13–21 and some models integrating gene mutations
and chromosomal alterations have been proposed.16,22,23 However,
the results are still controversial, probably due in part to the complex
mutational composition of the tumors and the possible interactions
between mutated genes and chromosomal alterations, which may
not be well captured in studies of limited number of genes and
samples.5,6 The global perspective of the whole-genome/exome
sequencing studies have provided new insights on the inﬂuence of
the genomic complexity in the evolution of the disease. These
studies uncovered that both the subclonal composition4,6 and
mutational complexity characterized by the accumulation of driver
alterations of the tumors5 impair the prognosis of the patients.
Moreover, initial studies using high-coverage next-generation
sequencing (NGS) have revealed the prognostic impact of mutations
present at very low allelic frequency.24–27 Together, these studies
suggest that understanding the heterogeneous evolution of CLL
may require the integration of the subclonal architecture and
mutational complexity of the tumors. Therefore, the aims of this
study were to deﬁne the deep mutational architecture of the most
frequently altered driver genes in CLL, and determine its relevance
in the progression of the disease.
MATERIALS AND METHODS
Patients and samples
We studied 406 previously untreated CLL patients (Table 1). Tumor cells
were puriﬁed from fresh or cryopreserved mononuclear cells.1 The median
ﬁnal fraction of tumor content was 98% (85% of the samples had 490%)
as determined by ﬂow cytometry. DNA was also extracted from puriﬁed
normal blood cells from the same patients (purity 497%, median 99.8%).
In 48 patients, longitudinal samples obtained at different time points of the
disease were also examined (Supplementary Table S1). Informed consent
was obtained from all patients according to the International Cancer
Genome Consortium (ICGC) guidelines.28 This study was approved by the
Hospital Clínic of Barcelona Ethics Committee.
Copy number analysis
Copy number alterations (CNA) were investigated using Genome-wide
Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA) in 376 cases and 44
sequential samples (Supplementary Methods).5 The proportion of tumor
cells (or cancer cell fraction, CCF) carrying each CNA was estimated from
the SNP array data (Supplementary Methods and Supplementary
Figure S1). CNA were considered as clonal if their CCF was ⩾ 85%, while
subclonal otherwise.6 CNA drivers were previously described.5
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Sequencing approach
The mutational status of 28 CLL driver genes was examined using a deep-
targeted NGS strategy in the 406 patients and 48 sequential samples. The
genes were TP53, SF3B1, BIRC3, NOTCH1 and ATM, recently analyzed for the
same cohort,26 and 23 additional genes (POT1, NFKBIE, ZNF292, XPO1, EGR2,
FBXW7, MGA, KLHL6, RPS15, MYD88, DDX3X, BRAF, NXF1, DTX1, BCOR,
CCND2, KRAS, IRF4, MED12, ZMYM3, NRAS, TRAF3 and PIM1), which were
selected among the most frequently mutated in prior whole-genome/
exome sequencing studies (Supplementary Table S2).5,6 Deep-targeted
NGS libraries were performed using the Access Array system (Fluidigm,
South San Francisco, CA, USA) (Supplementary Table S3) and/or the
Nextera XT DNA library preparation kit (Illumina, San Diego, CA, USA)
(Supplementary Table S4) before sequencing in a MiSeq equipment
(Illumina) (Supplementary Methods).
Mutational analysis
A mean coverage 41500× was obtained for nearly all targeted regions
(Supplementary Table S1). A previously validated bioinformatic pipeline26
allowed the detection of mutations down to 0.3% of variant allele
frequency (VAF) (Supplementary Methods and Supplementary Figure S2).
Synonymous variants and known polymorphisms (dbSNP142, 1000
Genomes Project, custom CLL database5) were automatically removed
(Supplementary Methods). Variants were considered somatic if they were
truncating or identiﬁed as somatic mutations in COSMIC (v72) or in our
custom CLL database.5 Variants not fulﬁlling the previous criteria were
investigated in the germ line DNA of the patients by NGS, Sanger
Table 1. Patients' baseline characteristics at the time of sampling
Parameter Category CLL (n= 406)
Gender % male/female 57/43
Age (years) Median (range) 66 (19–94)
Time from diagnosis to sampling
(months)
⩽ 12 206
412 200
Binet stage A 315
B 52
C 15
Unknown 24
Rai stage 0 254
I–II 110
III–IV 17
Unknown 25
Copy number alterations tri(12) 54/376 (14.3%)
del(13q) 163/376 (43.4%)
del(17p) 15/376 (4%)
del(11q) 37/376 (9.8%)
IGHV mutational status Mutated 218/382 (57.1%)
Patients treated during follow-up n (%) 211/406 (53%)
Follow-up from sampling (years) Median (range) 4.3 (0.01–19.1)
Abbreviations: Del, deletion; IGHV unmutated, ⩾ 98% identity with
germ line.
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Figure 1. Deep characterization of the mutational architecture of 28 CLL driver genes. (a) Pie chart of the proportion of cases grouped
according to their mutational clonality in the entire cohort of 406 patients (top-right corner). Percentage of cases carrying subclonal-low,
subclonal-high and clonal mutations in each gene. Only the mutation present at a higher CCF is represented in patients with multiple
mutations affecting the same gene. Genes with a Q-value o0.1 in the Kolmogorov–Smirnov test applied to test for uniform distribution of the
mutated CCFs are indicated. (b) Distribution of the CCF where each dot corresponds to the mutation of one patient. (c) Comparison of the
mutational frequency of each gene identiﬁed in this study (deep NGS, blue) with the previously published data from the CLL-ICGC project5
(only CLL cases considered (n= 428), orange), and DFCI/Broad series6 (only 123 pretreatment cases considered, yellow). Genes in which the
mutational frequency observed in the different studies statistically differs are indicated.
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sequencing or allele-speciﬁc (AS)-PCR (Supplementary Tables S5 and S6
and Supplementary Methods). Overall, only somatic and/or truncating
mutations were considered. All mutations reported at low VAF (o12%)
were veriﬁed by AS-PCR and/or a second independent round of NGS
(Supplementary Methods).
Estimation of the CCF of the mutations
The CCF carrying each speciﬁc mutation was calculated as follows:
CCFmut= (((q–2)CCFCNA+2)VAFmut)/p, where q is the copy locus number for
the sample, CCFCNA the CCF of the copy number alteration (0 to 1), VAFmut
the VAF of the mutation, and p the tumor purity of the sample (0 to 1). As
applied to the CNA, mutations were classiﬁed as clonal or subclonal if their
CCFs was ⩾ 85% or o85%, respectively. Given that mutations with very
low CCF were frequently identiﬁed in this study, subclonal mutations were
further classiﬁed as subclonal with high or low CCF (hereafter referred to as
‘subclonal-high’ and ‘subclonal-low’) using ⩾ 25% as cutoff. This cutoff
value, which corresponds to 12.5% of VAF, represents the common
detection threshold of mutations by Sanger sequencing.24,26
Inferring the temporal acquisition of alterations
First, we measured the variability in the estimation of the CNA and
mutation CCFs due to the SNP array and sequencing methodologies
(Supplementary Methods and Supplementary Figures S1 and S3). Next, we
tested for each alteration the enrichment of out-going edges (instances
where the alteration was present at a higher CCF than other alterations in
the same tumor) compared with in-going edges (the alteration was
present at a lower CCF than other alterations) and classiﬁed them as early,
late or intermediate (not powered to be classiﬁed neither early nor late)
events, as previously described.6 Temporal pairwise relationships were
analyzed for each pair of alterations connected by at least ﬁve out-/in-
going edges.6
Statistical methods
The prognostic impact was evaluated for time to ﬁrst treatment (TTFT) and
overall survival (OS) from the time of sampling. Deaths previous to any
treatment were considered as competing events for the TTFT analysis. The
Gray’s test was used for comparing cumulative incidence curves of TTFT,
while the log-rank test was used to compare Kaplan–Meier curves of OS.
Variables that were signiﬁcant in the univariate analyses were subse-
quently included in the multivariate analyses modeled using Fine-Gray and
Cox regression models for TTFT and OS, respectively.29 Backward-stepwise
elimination was used to identify variables with an independent prognostic
value. No differences were observed for TTFT and OS when comparing the
subset of samples collected within the ﬁrst year after diagnosis vs samples
obtained after the ﬁrst year (Supplementary Figure S4). Consequently, all
clinical analyses were performed using the whole series of patients.
Associations between variables were assessed by Fisher’s exact test,
Student’s t-test, Wilcoxon rank-sum test or Spearman's rank correlation
coefﬁcient, as appropriate. Kolmogorov–Smirnov test was used to test for
uniform distribution of the mutated CCFs. Maximally selected rank
statistics30 was applied to ﬁnd thresholds for continuous variables with
good prediction of clinical outcome (maxstat R package). P-values were
adjusted using the Benjamini–Hochberg correction (Q-value). P-values
o0.05 were considered signiﬁcant. All calculations were performed using
R (v3.2.4).31
RESULTS
Subclonal driver mutations are more common than clonal
mutations in CLL
We identiﬁed 609 mutations in 258 (64%) patients, 149 clonal, 201
subclonal-high and 259 subclonal-low (Supplementary Table S7).
Clonal mutations were seen in 28% of the patients, which were
the sole alterations in 10% and associated with additional
subclonal mutations in 18% (Figure 1a). Isolated subclonal
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Figure 2. Convergent mutational evolution (CME) in CLL driver genes. (a) Bar plots of the percentage of mutated cases carrying one or more
mutations in each gene. The Ph on the KLHL6 bar denotes that multiple mutations in this gene are mainly identiﬁed in the same allele (that is,
phased events). (b) Graphical representation of ATM (CLL296) and BCOR (CLL385 and CLL335) mutations identiﬁed in three different patients.
The CCF of each mutation is represented as a dot and the intervals show the sequencing variability. Histogram (bottom) shows the number of
CME events with mutations at similar CCFs, different CCFs or both. (c) Patterns of CME in the longitudinal analysis. Representation of two cases
in which mutations conferring CME for NOTCH1 and TP53, respectively, are acquired at different time points (left), and two cases with stable
CME (that is, similar CCF of the mutations in the two samples analyzed) for SF3B1, and NOTCH1 and ATM, respectively (right).
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mutations were found in 36% of the cases, 22% with high CCF
(subclonal-high) and 14% with low CCF (subclonal-low)
(Figure 1a). Remarkably, subclonal-low mutations were identiﬁed
as a sole abnormality in nearly all studied genes (26/28, 93%)
accounting for 6–63% of mutations per gene (median 38%)
(Figure 1a). Most genes showed a uniform continuous spectrum of
mutated CCFs with the exception of NOTCH1 and FBXW7 in which
most mutations were either clonal or subclonal-low; NXF1 and
DTX1 that were predominantly clonal; and TP53, NFKBIE and BIRC3
that were mostly subclonal (Figures 1a and b). Both clonal and
subclonal (high or low) mutations were located in the same
regions of the gene (Supplementary Figure S5), suggesting they
confer a similar selective advantage to the cell. Similarly, no
signiﬁcant differences were seen in the clinico-biological features
of the patients according to the clonal/subclonal distribution of
the mutations (Supplementary Figure S6). Since subclonal-low
mutations were frequent, the mutation rates observed for most
genes were signiﬁcantly higher than in previous whole-genome/
exome sequencing studies of untreated CLL patients (Figure 1c).5,6
Convergent mutational evolution is a common phenomenon in
CLL driver genes
Convergent mutational evolution (CME), considered as the
acquisition of more than one mutation in the same gene (ranging
from 2 to 5), was identiﬁed in 19 (68%) of the 28 genes studied
Figure 3. CLL architecture and temporal acquisition of driver alterations. (a) Graphical representation of the mutational and CNA status of the
406 untreated CLL cases studied. Cases are sorted based of their clonality as shown by the outer and innermost layers. The outer bar plot
represents the number of genes mutated with clonal and subclonal, only clonal, subclonal-high and subclonal-low mutations for each case.
The following inner layer represents the total number of driver alterations per case and the IGHV mutations. In the innermost layers, the basic
genetic alterations and the total number of driver CNA are shown. (b) Representation of CLL driver alterations according to their classiﬁcation
as early, late or intermediate events. Temporal relationships between speciﬁc pairs of alterations are represented by arrows. (c) Evolutionary
patterns observed in the longitudinal analysis regarding the driver CNA and gene mutations. Evol, evolution; mut, mutations (top). Mutations
acquired during the course of the disease before or after treatment (bottom). The P-value of the Wilcox test applied to compare the number of
mutations acquired in genes predicted as late events vs intermediate is shown.
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(Figure 2a). The number of cases with CME for a particular gene
signiﬁcantly correlated to its global mutational frequency (ρ= 0.72,
Po0.001). Overall, CME was observed in 66/406 (16%) of patients,
accounting for 26% (66/258) of all mutated cases. Of note,
multiple CME events affecting different genes within the same
tumor were found in eight cases. Patients with CME had a trend
towards a higher number of mutations in other genes (mean 2.23
vs 1.90, P= 0.072), but not CNA (mean 1.25 vs 1.14, P= 0.501),
compared with mutated cases without CME (Supplementary
Figure S7). The presence of CME was similarly observed across
patients with mutated or unmutated IGHV and was not associated
with age, Binet stage or clinical outcome (Supplementary Table S8
and Supplementary Figure S7).
A more detailed analysis of the CCFs of the mutations involved
in CME showed that mutations had similar CCFs in 50 CME events,
suggesting that they could represent either biallelic events or true
CME (Figure 2b). Our methodology could not completely
distinguish these two situations. A phasing analysis showed that
mutations were mostly found in independent alleles, with the
exception of KLHL6 in which virtually all mutations were present in
the same allele (data not shown). On the other hand, different
CCFs were observed in 24 CME events (6 of them carrying a mix of
similar and different CCFs), suggesting that these mutations
represented true CME events.
Besides, putative CME was identiﬁed in 10 of the 48 cases with
sequential samples (Supplementary Tables S1 and S9). In six cases
the CME were stable in both samples, whereas in four cases new
CME were observed in the second sample, conﬁrming that these
mutations may be acquired at different moments of the disease
(Figure 2c).
Subclonal architecture and evolutionary pathways in CLL
CNA were identiﬁed in 295/376 (78%) cases (range 1–26, median
2) (Supplementary Table S10), with no correlation between the
CNA and the number of mutations of the tumors (ρ= 0.18). Clonal
driver CNA (79%) were more frequently found than subclonal
(21%). Thus, 59% of the cases carried clonal driver CNA whereas
only 8% of the patients harbored isolated subclonal alterations
(Supplementary Figure S8).
Combining mutations and CNA, 86% (350/406) of patients
carried at least one driver alteration (range: 1–8, median: 2), which
was clonal in 66% (267/406) of cases (Figure 3a). Both clonal and
subclonal driver alterations were detected in 41% (166/406) of
patients whereas isolated subclonal driver alterations were seen in
19% (76/406) of cases (Figure 3a).
The deep sequencing with detailed information on the
spectrum of clonal–subclonal distribution of the mutations
together with CNA provided a thorough framework to reﬁne
their temporal relationship and hierarchical acquisition in CLL. The
distribution of CCFs of the CNA and mutations suggested a
scenario in which driver CNA are acquired earlier (mostly found
clonal), whereas gene mutations may be acquired at any time
during CLL evolution (found clonal and subclonal, indistinctly)
(Supplementary Figure S9). To provide a detailed estimation of the
temporal acquisition of individual alterations, we performed a
speciﬁc statistical analysis which conﬁrmed that CNA, particularly
tri(12), del(13q), del(11q) and del(17p), but also other less
recurrent CNA, are usually earlier events (Figure 3b and
Supplementary Table S11). On the other hand, gene mutations
were either late (NOTCH1, BIRC3, TP53, ZNF292, NFKBIE) or
intermediate (ATM, POT1, SF3B1, RPS15, among others) supporting
the idea that most mutations may be acquired at any time in the
evolution of the CLL and frequently later than CNA (Figure 3b).
The low mutational rate of CLL driver alterations as well as the
much lower sensitivity for detecting subclonal CNA are limitations
of this analysis. To overcome these limitations, we repeated the
analysis considering only mutations identiﬁed above the
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sensitivity detection of the CNA (CCF⩾ 25%). This analysis
conﬁrmed CNA as early or intermediate events (only two CNA
were classiﬁed as potentially late), while all gene mutations were
classiﬁed as late or intermediate (Supplementary Table S12).
In this temporal study, tri(12), del(17p) and del(11q) were initial
hits preceding the acquisition of NOTCH1, TP53 and ATM
mutations, respectively (Figure 3b, Supplementary Table S13 and
Supplementary Figure S10). The only hierarchic relationship in
individual gene mutations was found between RPS15 and NFKBIE.
Regarding the temporary acquisition of alterations in speciﬁc
pathways, only mutations in the NF-κB pathway could be deﬁned
as a later event than other driver mutations (Figure 3b and
Supplementary Table S14).
To conﬁrm this model we analyzed both the CNA and
mutational proﬁle in 44 sequential samples (Supplementary
Table S1). Most cases (39 cases, 89%) had a stable CNA proﬁle
in both samples. However, mutational evolution, considered as the
expansion of a preexisting mutated subclone or acquisition of new
mutations, was seen in 17 of them, 5 post-treatment and 12
previous to any treatment (Figure 3c). In three (7%) cases there
was a concomitant evolution of CNA and mutations correspond-
ing to del(17p) and TP53 mutations. Only two (5%) cases had
stable mutations and evolution of CNA (increase of tri(12) and a
heterozygous del(13q) becoming homozygous, respectively).
Moreover, acquisition of mutations in subsequent pretreatment
samples was mainly observed in genes predicted as late events in
the previous analysis (NOTCH1, NFKBIE, TP53, and BIRC3) compared
with intermediate events (P= 0.002; Figure 3c). Appearance of new
mutations in post-treatment samples was only observed in TP53
(n= 5) and BIRC3 (n= 1). All these analyses together suggest that
different CNA are the main initial events in CLL followed by an
increasing number of somatic mutations, which are mostly
acquired without any particular order among them
(Supplementary Figure S9).
The clinical relevance of mutated genes is related to their CCF
To determine whether the CCF of the mutations may inﬂuence the
outcome of the patients, we analyzed those genes mutated in
more than 10 cases with an algorithm that integrates maximally
selected rank statistics together with univariate continuous and
categorical analyses (Supplementary Methods and Supplementary
Figure S11). We identiﬁed three gene-speciﬁc CCF patterns
inﬂuencing prognosis (TTFT and/or OS): (1) CCF-independent
pattern: the mere detection of the mutation, even at very low
CCF, had prognostic impact (NFKBIE, BRAF, MGA, DDX3X, XPO1 and
POT1 for TTFT; TP53 and SF3B1 for OS) (Figure 4a and
Supplementary Figure S12); (2) CCF-gradual pattern: the prognos-
tic impact was related to the CCF of the mutated gene as a
continuous variable (RPS15, ATM, NOTCH1 and SF3B1 for TTFT)
(Figure 4a and Supplementary Figure S12); and (3) CCF-dominant
pattern: the mutated gene had prognostic impact only when its
CCF was above a certain threshold (FBXW7, and NOTCH1 for OS)
(Figure 4a). A summary of the clinical impact and CCF-based
pattern identiﬁed for each gene is shown in Supplementary
Table S16.
Several mutated genes with prognostic impact were signiﬁ-
cantly co-occurring in the same tumors (Figure 4b). To identify
which of them had an independent value we performed a
backward-stepwise regression analysis including the mutated
genes with prognostic impact in the univariate analysis together
with high-risk CNA (del(17p), del(11q)), IGHV mutational status and
clinical parameters (gender, age, Binet stage). This analysis
revealed that SF3B1, BRAF, ATM, NOTCH1 and MGA mutations
had independent prognostic impact for TTFT, while mutations in
FBXW7, NOTCH1, SF3B1 and TP53 had independent value for OS
(Table 2).
Tumor architecture predicts CLL progression and outcome
Finally, we explored the prognostic value of the global tumor
architecture compared with individual alterations and standard
parameters of poor prognosis. First, we conﬁrmed the unfavorable
outcome of patients carrying subclonal driver alterations (muta-
tions and/or CNA),4,6 and the progressively worse effect on
outcome of the accumulation of driver alterations (1 to ⩾ 4)
(Supplementary Figure S13).5 However, patients with subclonal
populations harbored higher number of driver alterations,
suggesting that these variables may be correlated (Figure 5a).
Therefore, we tested separately the number of driver alterations
(0 to ⩾ 4) in clonal tumors (that is, all aberrations were clonal), and
the accumulation of clonal and subclonal driver alterations in
cases that had at least one subclonal driver aberration (0 to ⩾ 4)
(number of driver alterations in subclonal tumors).
Figure 4. CCF-based patterns with prognostic impact. (a) Time to
ﬁrst treatment (TTFT) or overall survival (OS) curves of some
representative mutated genes that follow a CCF-independent (top),
CCF-gradual (middle) or CCF-dominant pattern (bottom) with
impact on the outcome of the patients. The cutoff obtained by
maxstat is shown on the top of the curves included in the
CCF-dominant pattern. P-values for all pairwise comparisons are
shown inside the plot areas. P, P-values by Gray’s test (TTFT) or log-
rank test (OS). (b) Heat map of the co-occurrence of the driver
alterations identiﬁed in ⩾ 10 cases and IGHV mutational status by
representing the adjusted P-value (Q-value) of the Fisher’s exact test.
Mutated genes with clinical impact in the univariate analysis are
depicted in bold.
Table 2. Mutated genes with independent prognostic value for TTFT and OS
Multivariate Fine-Gray regression model for TTFT Multivariate Cox regression model for OS
Variable HR (95% CI) P-value Variable HR (95% CI) P-value
IGHV (unmut vs. mut) 2.41 (1.66–3.48) o0.001 Age at sampling (465 vs ⩽ 65 years) 2.50 (1.53–4.07) o0.001
Binet stage (B/C vs A) 2.76 (1.95–3.89) o0.001 del(17p) (presence vs absence) 5.65 (2.59–12.3) o0.001
SF3B1 (mut vs unmut) 1.80 (1.28–2.54) o0.001 IGHV (unmut vs mut) 2.29 (1.43–3.69) 0.001
BRAF (mut vs unmut) 2.23 (1.18–4.21) 0.013 FBXW7 (mut CCF⩾ 52 vs unmut/mut CCF o52%) 5.50 (2.07–14.6) 0.001
ATM (mut vs unmut) 1.58 (1.09–2.29) 0.015 NOTCH1 (mut CCF⩾ 63% vs unmut/mut CCF o63%) 2.08 (1.20–3.61) 0.009
NOTCH1 (mut vs unmut) 1.45 (1.05–2.00) 0.025 SF3B1 (mut vs unmut) 2.03 (1.15–3.57) 0.015
MGA (mut vs unmut) 1.82 (1.05–3.15) 0.033 TP53 (mut w/o del(17p) vs unmut/mut with del(17p)) 1.97 (1.01–3.82) 0.045
N= 359, events= 188, competing events= 27. Starting model: IGHV, Binet stage, age at sampling, gender, del(17p) (with or without TP53 mutation), del(11q)
(with or without ATM mutation), NOTCH1, SF3B1, ATM (without del(11q)), POT1, NFKBIE, XPO1, MGA, RPS15, DDX3X and BRAF mutations. N= 319, events= 84.
Starting model: IGHV, Binet stage, age at sampling, gender, del(17p) (with or without TP53 mutation), del(11q) (with or without ATM mutation), NOTCH1, SF3B1,
FBXW7 and TP53 (without del(17p)) mutations.
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The number of drivers in both clonal and subclonal tumors
gradually shortened the TTFT of the patients with a similar
prognostic value (Figure 5b). A multivariate model including also
other markers of poor prognosis (IGHV mutations, Binet stage, age,
gender, and SF3B1, TP53 and ATM status) revealed that the
number of driver alterations retained its independent prognostic
value for TTFT (Table 3). These results suggest that the number of
drivers, rather than their clonal/subclonal representation, is the
main predictor for short TTFT.
Regarding OS, the number of drivers in subclonal tumors, but
not in clonal tumors, was steadily associated with a worse
outcome (Figure 5c). However, a multivariate analysis showed that
the prognostic value of this parameter was not independent of
the age of the patients and the IGHV and TP53 status of the
tumors (Supplementary Table S17).
Of note, these results were unaffected by the use of different
CCF cutoffs (70–95%) for deﬁning the category of clonal/subclonal
alterations (data not shown). All these ﬁndings suggest that in
untreated patients the accumulation of driver alterations inﬂu-
ences the rapid need for treatment independently of the
subclonal composition of the tumors and standard prognostic
parameters. In contrast, the increasing subclonal diversity, rather
than the simple accumulation of driver alterations, is associated
with a shorter OS of the patients, although this is mainly explained
by their age, IGHV and TP53 status.
DISCUSSION
The highly sensitive NGS strategy used in this study identiﬁed
frequent small subclonal mutations in virtually all genes, including
MYD88 and RPS15, previously considered as early clonal events in
CLL.4,6,19 These small subclonal mutations were undetected in
previous WG/WE/Sanger sequencing studies. Consequently, the
frequency of mutations for most of these drivers is higher than
previously considered.5,6 Intriguingly, isolated subclonal mutations
were more common than clonal mutations (55 vs 45% of mutated
cases), suggesting that these aberrations are not initiating events
in most CLL cases. These results were concordant with the analysis
of the temporal acquisition of genomic alterations which
conﬁrmed CNA as frequent early events6 usually followed by the
acquisition of somatic mutations. The longitudinal analysis of 44
cases conﬁrmed this model accentuating that CNA tend to be
stable during the course of the disease, whereas gene mutations
are continually acquired during CLL evolution, which may evolve
until becoming the major clone, even without treatment pressure.
Although particular CNA tend to precede the acquisition of
speciﬁc mutations (for example, tri(12) and NOTCH1 mutations, del
(11q) and ATM mutations, among others), we did not ﬁnd a
stringent hierarchical pattern that could deﬁne the temporal order
of acquisition of mutated genes. This is in contrast to myelodys-
plastic syndromes, in which early gene mutations seem to dictate
the future acquisition of certain alterations.32 Intriguingly, contrary
to previous observations,6 our clonal analysis revealed that del
(17p) may precede TP53 mutations in CLL, as we did not ﬁnd any
case with del(17p) at lower CCF than mutations. On the other
hand, concomitant evolution of del(17p) and TP53 mutated
subclones was observed in longitudinal samples conﬁrming
previous hypotheses.6 Of note, isolated del(17p) are rare
compared with isolated TP53 mutations (3 vs 28 cases) emphasiz-
ing that just performing FISH analysis will underestimate the
number of TP53 alterations (Supplementary Figure S10). The
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Figure 5. Role of the subclonal architecture and mutational
complexity in CLL evolution. (a) Boxplots of the number of driver
alterations in patients with or without a subclonal driver alteration
(left). Boxplots dividing the group of patients with a subclonal driver
present in three groups regarding their clonality: cases with clonal
and subclonal, subclonal-high and only subclonal-low alterations
(right). (b) Comparison of TTFT between patients carrying 0, 1, 2, 3 or
⩾ 4 driver alterations in the subgroup of patients with subclonal
(left) or clonal tumors (right). (c) Survival curves according to the
number of driver alterations in the subgroup of patients carrying
subclonal (left) or clonal tumors (right).
Table 3. Independent prognostic value of the accumulation of driver
alterations for TTFT
Variable HR (95% CI) P-value
Binet stage (B/C vs A) 2.44 (1.60–3.74) o0.001
No. drivers (0, 1, 2, 3, ⩾ 4) 1.44 (1.21–1.72) o0.001
SF3B1 (mut vs unmut) 2.02 (1.39–2.94) o0.001
IGHV (unmut vs mut) 2.07 (1.35–3.19) 0.001
ATM (mut/deletion vs wt) 1.82 (1.19–2.27) 0.006
Age at sampling (465 vs ⩽ 65 years) 0.66 (0.48–0.91) 0.011
N= 307, events= 146, competing events= 27. Starting model: IGHV, Binet
stage, age at sampling, gender, TP53 aberration (mutation/deletion), ATM
aberration (mutation/deletion), SF3B1 mutation and number of driver
alterations (not including TP53, ATM and SF3B1 mutations, neither del(17p)
nor del(11q)).
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interpretation of these ﬁndings is complex but may suggest that
at least some of the mutations may be dominant negative with
less pressure to select deletions of normal alleles.33,34
CME has been identiﬁed in occasional CLL cases, particularly
involving TP53, SF3B1, NOTCH1, BIRC3 and DDX3X.7,8,26 Our study
shows that CME is a common phenomenon in CLL (26% of
mutated cases) and occurs in most studied genes (68%). The CCF
analysis of the mutations conferring CME highlights the need to
differentiate among true CME, biallelic or phased events. Our
longitudinal analysis suggests that mutations conferring CME are
acquired at different stages of the disease and may evolve to
reach an interclonal equilibrium. The high incidence of CME
together with the frequent detection of small mutated subclones
reﬂects the plasticity of CLL and emphasizes the relevance of
speciﬁc driver genes for the evolution of the disease.
Previous studies have shown the clinical impact of small
mutated subclones of TP53 or NOTCH1.24–27,35 The current study
extends these observations to other CLL driver genes (NFKBIE,
BRAF, MGA, RPS15 or POT1, among others) and identiﬁes that the
prognostic impact of some of them may be related to the
quantitative representation of the mutated subclone. The
quantiﬁcation of the mutational CCF of the tumors, once
conﬁrmed in independent cohorts, may need to be considered
in the development of prognostic models based on the
mutational proﬁle of the tumors.16,22
Different studies have identiﬁed several mutated genes with
prognostic impact in CLL.1,2,5,6,13–21 We have observed that a
number of them tend to occur simultaneously in the same tumors.
Here, we have identiﬁed the mutated genes that independently
shortened TTFT (SF3B1, BRAF, ATM, NOTCH1, MGA) and OS (FBXW7,
NOTCH1, SF3B1, TP53). This information may be useful to design
the panel of relevant genes for future studies. In addition to
individual genes, recent genomic studies have suggested that
understanding the whole tumor architecture, rather than indivi-
dual driver alterations, may be crucial to assess the prognosis of
the patients. These studies identiﬁed the accumulative number of
alterations per tumor5 or the presence of driver subclones4,6 as
promising parameters to improve the evaluation of CLL outcome.
Our results showed that the total number of driver alterations
(mutational complexity), regardless if they were clonal or
subclonal, steadily shortened the TTFT and this was independent
of the IGHV, Binet stage, and ATM, TP53 and SF3B1 status. The
number of driver alterations in our study includes both mutated
genes and CNA. Therefore, this ﬁnding expands the prognostic
value of the karyotype complexity observed in previous
studies.20,36–39 This observation is similar to the impact of driver
mutations in myelodysplastic syndromes in which the evolution of
the patients progressively deteriorated as the number of driver
mutations increased.32
Conversely, our analysis reveals that the OS of the CLL patients
seems more inﬂuenced by the subclonal diversity of the tumors
rather than the number of driver alterations. Thus, the increasing
accumulation of driver alterations only shortened the OS in
tumors with subclonal populations (subclonal tumors). On the
contrary, patients with clonal tumors, independently of their
number of alterations, had a similar outcome than cases without
driver alterations. However, the prognostic value of the subclonal
diversity was not independent of age, IGHV and TP53 status. Our
ﬁndings highlight the relevance of these factors in the survival of
the patients treated with the available strategies. However, novel
treatments are inﬂuencing the outcome of the patients and these
parameters will need to be reevaluated in these new contexts.
In conclusion, we identiﬁed the relevance of the subclonal
architecture and mutational complexity in the evolution of CLL.
The progressive accumulation of driver alterations gradually
shortened the TTFT independently of the clonal architecture,
whereas the OS of the patients was inﬂuenced by the increasing
diversity of the subclonal composition of the tumors, although this
phenomenon seemed to be related to the IGHV and TP53 status.
Our study has also identiﬁed relevant mutated genes that may
orient the design of speciﬁc gene panels for future studies.
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